The short-chain branched fatty acid, valproic acid (2-propylpentanoicacid), has long been in use clinically as an anticonvulsant and mood-stabilizing drug. Recently, VPA has been shown to inhibit the activity of histone deacetylases (HDACs), resulting in chromatin remodelling and changes in gene expression. Although the molecular mechanism for VPA action in the central nervous system (CNS) is n...

Neuroinflammation is recognized as a major factor in Parkinson's disease (PD) pathogenesis and increasing evidence propose that microglia is the main source of inflammation contributing to the dopaminergic degeneration observed in PD. Several studies suggest that astrocytes could act as physiological regulators preventing excessive microglia responses. However, little is known regarding how ast...

Here, we describe the generation of viable and dopamine-producing neurons derived from pluripotent mouse embryonic stem cells. Neurotrophic factors in combination with survival-promoting factors, such as interleukin-1beta, glial cell line-derived neurotrophic factor, neurturin, transforming growth factor-beta(3) and dibutyryl-cyclic AMP, significantly enhanced Nurr1 and tyrosine hydroxylase (TH...

Zuckerkandl’s organ (ZK) is an extra adrenal para-ganglion and has the ability to express glial cell line derived neurotrophic factor (GDNF) and transforming growth factor (TGF). It is also a source of dopamine and norepinephrine. In the present study, the neuroprotective and restorative potential of ZK was studied by transplanting it into the striatum of adult rats either before or after the i...

Parkinson's disease (PD) is a progressive and age-associated neurodegenerative disorder. Patients at different stages of the disease course have distinguished features, mainly in the number of dopaminergic neurons. Cerebral dopamine neurotrophic factor (CDNF) is a recently discovered neurotrophic factor, being deemed as a hopeful candidate for PD treatment. Here, we evaluated the efficacy of CD...

Apomorphine, the catechol-derived dopamine D1/D2 receptor agonist, is currently in use as an antiparkinsonian drug. It has previously been reported that apomorphine was able to elicit expression of the enzyme tyrosine hydroxylase, a marker for DA neurons, in the fetal rat cerebrocortical cultures whilst in the presence of brain-derived neurotrophic factor. The present study demonstrated that tr...

Cerebral dopamine neurotrophic factor (CDNF) protein has been shown to protect the nigrostriatal dopaminergic pathway when given as intrastriatal infusions in rat and mouse models of Parkinson's disease (PD). In this study, we assessed the neuroprotective effect of CDNF delivered with a recombinant adeno-associated viral (AAV) serotype 2 vector in a rat 6-hydroxydopamine (6-OHDA) model of PD. A...

The symptoms of Parkinson's disease occur due to degeneration of dopamine neurons in substantia nigra. It has been demonstrated that glial cell line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor when it comes to protect and enhance survival of dopamine neurons in animal models of Parkinson's disease. The aim of this study was to evaluate shortand long-term effects of GDNF o...

1. Review of the literature ..........................................................................................1 1.1. Brain dopaminergic system ..................................................................................... 1 1.1.1. Development of the midbrain dopaminergic system ............................ 2 1.2. Parkinson’s disease...................................................

The complex biology of Parkinson's disease and the obscure mechanism of dopaminergic cell death in the course of the disease indicate that multiple intracellular pathways and numerous crucial elements contribute to the demise of these neurons. Therefore, multi-factorial approaches would more likely confer long-lasting survival and potentiate the biological function of dopamine neurons. We are p...